Precisely, in CRC cases with a mutated (MT) form of BRAF or ARID2, the protein expression levels of BRAF or ARID2 were significantly lower compared to cases with the wild-type (WT) form (p = 0.022, Figures 10A–C for BRAF; p = 0.0008, Figures 10G–I for ARID2). This evidence concerns the gene BRAF and colorectal carcinoma.